ASC618
ASC618 (also known as AAV2/8 HCB-ET3-LCO BDD FVIII) is an experimental gene therapy for Hemophilia A. It was developed by Applied StemCell Therapeutics and is delivered via a hybrid of adeno-associated virus types 2 and 8. The gene therapy is hoped to be more effective than earlier gene therapies for hemophilia A.
Wikipedia contributors, "ASC618", Wikipedia, revision 1252675274, retrieved 20 November 2026, source, CC BY-SA 4.0.